The impact of antiviral therapy for hepatitis C on the quality of life: a perspective

Liver International

Volumn 37, Issue , 2017, Pages 7-12

  Dusheiko, Geoffrey ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

antiviral treatment; health related quality of life; hepatitis C; interferon; patient reported outcomes; sofosbuvir

Indexed keywords

ANTIVIRUS AGENT; PEGINTERFERON; RIBAVIRIN; ALPHA INTERFERON; SOFOSBUVIR;

ANTIVIRAL THERAPY; CLINICAL TRIAL (TOPIC); HEPATITIS C; HISTORY; HUMAN; MORBIDITY; MORTALITY; PATIENT-REPORTED OUTCOME; PRODUCTIVITY; QUALITY OF LIFE; REVIEW; SUSTAINED VIROLOGIC RESPONSE; SYSTEMATIC REVIEW (TOPIC); CHRONIC HEPATITIS C; COMBINATION DRUG THERAPY; HEPACIVIRUS;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; QUALITY OF LIFE; SOFOSBUVIR; SUSTAINED VIROLOGIC RESPONSE;

EID: 85007583476     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13292     Document Type: Review

References (59)

1. Chan K, Lai MN, Groessl EJ, et al. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration. Clin Gastroenterol Hepatol. 2013;11:1503–1510.
2. Younossi Z, Henry L. The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C. Dig Liver Dis. 2014;46(Suppl 5):S186–S196.
3. Younossi Z, Henry L. Systematic review: patient-reported outcomes in chronic hepatitis C—the impact of liver disease and new treatment regimens. Aliment Pharmacol Ther. 2015;41:497–520.
4. Younossi ZM, Kanwal F, Saab S, et al. The impact of hepatitis C burden: an evidence-based approach. Aliment Pharmacol Ther. 2014;39:518–531.
5. Younossi ZM, Stepanova M, Nader F, Lam B, Hunt S. The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon- and ribavirin-free regimens: a study of health-related quality of life. Aliment Pharmacol Ther. 2015;42:286–295.
6. Hartwell D, Cooper K, Frampton GK, Baxter L, Loveman E. The clinical effectiveness and cost-effectiveness of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people: a systematic review and economic evaluation. Health Technol Assess (Winchester, England). 2014;18: i-xxii, 1–202.
7. Mhatre SK, Sansgiry SS. Development of a conceptual model of health-related quality of life among hepatitis C patients: a systematic review of qualitative studies. Hepatol Res. 2016;46:29–39.
8. Smith-Palmer J, Cerri K, Valentine W. Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. BMC Infect Dis. 2015;15:19.
9. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014;61(1 Suppl):S58–S68.
10. Curry MP, Forns X, Chung RT, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology. 2015;148:100–107 e101.
11. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60:392–420.
12. Wedemeyer H, Dore GJ, Ward JW. Estimates on HCV disease burden worldwide—filling the gaps. J Viral Hepatitis. 2015;22(Suppl 1):1–5.
13. Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet. 2015;385:1124–1135.
14. Saab S, Hunt DR, Stone MA, McClune A, Tong MJ. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model. Liver Transpl. 2010;16:748–759.
15. Butt AA, Yan P, Lo Re V 3rd, et al. Liver fibrosis progression in hepatitis C virus infection after seroconversion. JAMA Intern Med. 2015;175:178–185.
16. McCombs J, Matsuda T, Tonnu-Mihara I, et al. The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry. JAMA Intern Med. 2014;174:204–212.
17. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584–2593.
18. van der Meer AJ. Achieving sustained virological response: what's the impact on further hepatitis C virus-related disease? Expert Rev Gastroenterol Hepatol. 2015;9:559–566.
19. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45:529–538.
20. Leidner AJ, Chesson HW, Xu F, Ward JW, Spradling PR, Holmberg SD. Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease. Hepatology (Baltimore, MD). 2015;61:1860–1869.
21. Berenguer J, Alvarez-Pellicer J, Martin PM, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology (Baltimore, MD). 2009;50:407–413.
22. Lee MH, Yang HI, Lu SN, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis. 2012;206:469–477.
23. Negro F, Forton D, Craxi A, Sulkowski MS, Feld JJ, Manns MP. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology. 2015;149:1345–1360.
24. Metwally AH, Elgamal MA. The relation between hepatitis C virus and coronary heart disease. Med Hypotheses. 2014;82:505.
25. Lin MS, Guo SE, Chen MY, et al. The impact of hepatitis C infection on ischemic heart disease via ischemic electrocardiogram. Am J Med Sci. 2014;347:478–484.
26. Cacoub P, Desbois AC, Isnard-Bagnis C, Rocatello D, Ferri C. Hepatitis C virus infection and chronic kidney disease: time for reappraisal. J Hepatol. 2016;65(1 Suppl):S82–S94.
27. Cacoub P, Comarmond C, Domont F, Savey L, Saadoun D. Cryoglobulinemia vasculitis. Am J Med. 2015;128:950–955.
28. Cacoub P, Comarmond C, Domont F, Savey L, Desbois AC, Saadoun D. Extrahepatic manifestations of chronic hepatitis C virus infection. Ther Adv Infect Dis. 2016;3:3–14.
29. Fabrizi F, Plaisier E, Saadoun D, Martin P, Messa P, Cacoub P. Hepatitis C virus infection, mixed cryoglobulinemia, and kidney disease. Am J Kidney Dis. 2013;61:623–637.
30. Petta S, Maida M, Macaluso FS, et al. Hepatitis C virus infection is associated with increased cardiovascular mortality: a meta-analysis of observational studies. Gastroenterology. 2016;150:145–155.e144; quiz e115-146.
31. Petta S, Torres D, Fazio G, et al. Carotid atherosclerosis and chronic hepatitis C: a prospective study of risk associations. Hepatology (Baltimore, MD). 2012;55:1317–1323.
32. Ware JE Jr, Bayliss MS, Mannocchia M, Davis GL. Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group. Hepatology. 1999;30:550–555.
33. McHutchison JG, Ware JE Jr, Bayliss MS, et al. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol. 2001;34:140–147.
34. Foster GR. Quality of life considerations for patients with chronic hepatitis C. J Viral Hepat. 2009;16:605–611.
35. Rosa K, Fu M, Gilles L, et al. Validation of the Fatigue Severity Scale in chronic hepatitis C. Health Qual Life Outcomes. 2014;12:90.
36. Strauss E, Porto-Ferreira FA, de Almeida-Neto C, Teixeira MC. Altered quality of life in the early stages of chronic hepatitis C is due to the virus itself. Clin Res Hepatol Gastroenterol. 2014;38:40–45.
37. Younossi ZM, Stepanova M, Nader F, et al. Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens. Hepatology. 2014;59:2161–2169.
38. Gilli SC. Scientific comment on health-related quality of life among blood donors with hepatitis B and hepatitis C: longitudinal study before and after diagnosis? Revista brasileira de hematologia e hemoterapia. 2015;37:369–370.
39. Matza LS, Sapra SJ, Dillon JF, et al. Health state utilities associated with attributes of treatments for hepatitis C. Eur J Health Econ. 2015;16:1005–1018.
40. Zalai D, Sherman M, McShane K, Shapiro CM, Carney CE. The importance of fatigue cognitions in chronic hepatitis C infection. J Psychosom Res. 2015;78:193–198.
41. Armstrong AR, Herrmann SE, Chassany O, et al. The International development of PROQOL-HCV: an instrument to assess the health-related quality of life of patients treated for hepatitis C virus. BMC Infect Dis. 2016;16:443.
42. Doyle JS, Grebely J, Spelman T, et al. Quality of life and social functioning during treatment of recent hepatitis C infection: a multi-centre prospective cohort. PLoS One. 2016;11:e0150655.
43. Leidner AJ, Chesson HW, Spradling PR, Holmberg SD. Assessing the effect of potential reductions in non-hepatic mortality on the estimated cost-effectiveness of hepatitis C treatment in early stages of liver disease. Appl Health Econ Health Policy. 2016; DOI: 10.1007/s40258-016-0261-2
44. Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology. 1999;29:264–270.
45. Arase Y, Suzuki F, Suzuki Y, et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology. 2009;49:739–744.
46. Arase Y, Kobayashi M, Kawamura Y, et al. Impact of virus clearance for the development of hemorrhagic stroke in chronic hepatitis C. J Med Virol. 2014;86:169–175.
47. Byrnes V, Miller A, Lowry D, et al. Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition. J Hepatol. 2012;56:549–556.
48. Hsu YC, Lin JT, Ho HJ, et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology. 2014;59:1293–1302.
49. Hsu YC, Ho HJ, Huang YT, et al. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut. 2015;64:495–503.
50. Maruyama S, Koda M, Oyake N, et al. Myocardial injury in patients with chronic hepatitis C infection. J Hepatol. 2013;58:11–15.
51. Stepanova M, Nader F, Cure S, Bourhis F, Hunt S, Younossi ZM. Patients’ preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens. Aliment Pharmacol Ther. 2014;40:676–685.
52. Whiteley D, Elliott L, Cunningham-Burley S, Whittaker A. Health-related quality of life for individuals with hepatitis C: a narrative review. Int J Drug Policy. 2015;26:936–949.
53. Younossi ZM, Stepanova M, Feld J, et al. Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: results from ASTRAL-1 placebo-controlled trial. J Hepatol. 2016;65:33–39.
54. Younossi ZM, Stepanova M, Henry L. Performance and Validation of Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV) in clinical trials of patients with chronic hepatitis C. Value Health. 2016;19:544–551.
55. Younossi ZM, Stepanova M, Henry L, et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C). J Hepatol. 2014;60:741–747.
56. Younossi ZM, Stepanova M, Nader F, Henry L. Patient-reported outcomes of elderly adults with chronic hepatitis C treated with interferon- and ribavirin-free regimens. J Am Geriatr Soc. 2016;64:386–393.
57. Younossi ZM, Stepanova M, Sulkowski M, et al. Ribavirin-free regimen with sofosbuvir and velpatasvir is associated with high efficacy and improvement of patient-reported outcomes in patients with genotypes 2 and 3 chronic hepatitis C: results from Astral-2 and -3 clinical trials. Clin Infect Dis. 2016;63:1042–1048.
58. Younossi ZM, Stepanova M, Sulkowski M, Naggie S, Henry L, Hunt S. Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus. J Viral Hepat. 2016;23:857–865.
59. Natarajan Y, White DL, El-Serag HB, et al. Role of non-hepatic medical comorbidity and functional limitations in predicting mortality in patients with HCV. Dig Dis Sci. 2016; DOI: 10.1007/s10620-016-4303-2